Bausch + Lomb Research and Development Expenses 2021-2023 | BLCO
Bausch + Lomb annual/quarterly research and development expenses history and growth rate from 2021 to 2023. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Bausch + Lomb research and development expenses for the quarter ending December 31, 2023 were $0.080B, a 2.56% increase year-over-year.
- Bausch + Lomb research and development expenses for the twelve months ending December 31, 2023 were $324M, a 5.54% increase year-over-year.
- Bausch + Lomb annual research and development expenses for 2023 were $0.324B, a 5.54% increase from 2022.
- Bausch + Lomb annual research and development expenses for 2022 were $0.307B, a 13.28% increase from 2021.
- Bausch + Lomb annual research and development expenses for 2021 were $0.271B, a 7.11% increase from 2020.
| Bausch + Lomb Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2023 | $324 |
| 2022 | $307 |
| 2021 | $271 |
| 2020 | $253 |
| Bausch + Lomb Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2023-12-31 | $80 |
| 2023-09-30 | $82 |
| 2023-06-30 | $85 |
| 2023-03-31 | $77 |
| 2022-12-31 | $78 |
| 2022-09-30 | $77 |
| 2022-06-30 | $75 |
| 2022-03-31 | $77 |
| 2021-12-31 | $70 |
| 2021-09-30 | $63 |
| 2021-06-30 | $71 |
| 2021-03-31 | $67 |
| 2020-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $5.109B | $4.146B |
| Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R). Bausch Lomb Corporation is based in VAUGHAN, ON. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $122.851B | 15.41 |
| Cencora (COR) | United States | $47.686B | 19.03 |
| ICON (ICLR) | Ireland | $24.574B | 23.20 |
| DiDi Global (DIDIY) | China | $24.011B | 0.00 |
| Avantor (AVTR) | United States | $16.459B | 24.23 |
| Viatris (VTRS) | United States | $13.776B | 3.96 |
| CochLear (CHEOY) | Australia | $13.705B | 0.00 |
| Revvity (RVTY) | United States | $12.658B | 22.18 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.086B | 0.00 |
| Medpace Holdings (MEDP) | United States | $12.032B | 39.59 |
| Charles River Laboratories (CRL) | United States | $11.796B | 21.50 |
| Natera (NTRA) | United States | $11.354B | 0.00 |
| Solventum (SOLV) | United States | $11.215B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $8.201B | 0.00 |
| HealthEquity (HQY) | United States | $6.770B | 50.58 |
| Organon (OGN) | United States | $4.786B | 4.61 |
| Doximity (DOCS) | United States | $4.531B | 33.74 |
| PACS (PACS) | United States | $3.749B | 0.00 |
| Surgery Partners (SGRY) | United States | $3.171B | 29.35 |
| Sotera Health (SHC) | United States | $3.170B | 15.56 |
| Progyny (PGNY) | United States | $3.081B | 51.71 |
| GoodRx Holdings (GDRX) | United States | $2.804B | 142.00 |
| Life Times (LTH) | United States | $2.687B | 29.70 |
| Premier (PINC) | United States | $2.502B | 9.16 |
| AMN Healthcare Services Inc (AMN) | United States | $2.273B | 7.35 |
| Agilon Health (AGL) | United States | $2.261B | 0.00 |
| Teladoc Health (TDOC) | United States | $2.162B | 0.00 |
| BrightSpring Health Services (BTSG) | United States | $1.830B | 0.00 |
| Agiliti (AGTI) | United States | $1.381B | 22.56 |
| Establishment Labs Holdings (ESTA) | $1.373B | 0.00 | |
| NovoCure (NVCR) | Jersey | $1.317B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $0.982B | 0.00 |
| Pediatrix Medical (MD) | United States | $0.745B | 7.71 |
| Embecta (EMBC) | United States | $0.583B | 3.85 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.531B | 0.00 |
| Enhabit (EHAB) | United States | $0.506B | 45.86 |
| Auna S.A (AUNA) | Luxembourg | $0.503B | 0.00 |
| LifeMD (LFMD) | United States | $0.488B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.482B | 0.00 |
| GeneDx Holdings (WGS) | United States | $0.445B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.437B | 0.00 |
| MultiPlan (MPLN) | United States | $0.419B | 0.00 |
| CareDx (CDNA) | United States | $0.402B | 0.00 |
| Beauty Health (SKIN) | United States | $0.399B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.379B | 0.00 |
| DocGo (DCGO) | United States | $0.352B | 56.33 |
| ModivCare (MODV) | United States | $0.333B | 4.42 |
| Ascend Wellness Holdings (AAWH) | United States | $0.304B | 0.00 |
| Sharecare (SHCR) | United States | $0.259B | 0.00 |
| Biodesix (BDSX) | United States | $0.142B | 0.00 |
| So-Young (SY) | China | $0.129B | 43.33 |
| Oncology Institute (TOI) | United States | $0.079B | 0.00 |
| Pono Capital Two (PTWO) | United States | $0.071B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.054B | 0.00 |
| NeueHealth (NEUE) | United States | $0.052B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.036B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.036B | 0.00 |
| Nutex Health (NUTX) | United States | $0.030B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.030B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.029B | 0.00 |
| DermTech (DMTK) | United States | $0.021B | 0.00 |
| OncoCyte (OCX) | United States | $0.021B | 0.00 |
| Aesthetic Medical Hldngs Group (AIH) | China | $0.014B | 0.00 |
| BIMI Holdings (BIMI) | United States | $0.014B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.011B | 0.00 | |
| TRxADE HEALTH (MEDS) | United States | $0.008B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.007B | 0.00 |
| OpGen (OPGN) | United States | $0.005B | 0.00 |
| Assure Holdings (IONM) | United States | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |